Disease Domain | Count |
---|---|
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Herbal medicine | 1 |
Recombinant polypeptide | 1 |
Top 5 Target | Count |
---|---|
FGFs(Fibroblast growth factors) | 1 |
Target |
Mechanism FGFs modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Nov 2024 |
Sponsor / Collaborator |
Start Date18 Mar 2024 |
Sponsor / Collaborator |
Start Date08 Mar 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
ES-135 ( FGFs ) | Spinal Cord Injuries More | Phase 3 |
Shenghua Decoction | Postpartum Hemorrhage More | Clinical |